Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Leukemia

Volumn 27, Issue 1, 2013, Pages 66-74

  Etchin, J ^a   Sun, Q ^b   Kentsis, A ^a   Farmer, A ^b   Zhang, Z C ^b   Sanda, T ^a   Mansour, M R ^a   Barcelo, C ^a   McCauley, D ^c   Kauffman, M ^c   Shacham, S ^c   Christie, A L ^a   Kung, A L ^a   Rodig, S J ^d   Chook, Y M ^b   Look, A T ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Karyopharm Therapeutics   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AML; CRM1; nuclear export inhibitors

Indexed keywords

ANTILEUKEMIC AGENT; CHROMOSOME REGION MAINTENANCE 1 PROTEIN; PROTEIN; PROTEIN INHIBITOR; SELECTIVE INHIBITORS OF NUCLEAR EXPORT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CRYSTAL STRUCTURE; EXPRESSION VECTOR; HEMATOPOIETIC CELL; LEUKEMIA CELL LINE; MOLECULAR CLONING; MOLECULAR MODEL; MOUSE; NONHUMAN; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; KARYOPHERINS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEAR EXPORT SIGNALS; NUCLEAR PROTEINS; PROTEIN BINDING; RAN GTP-BINDING PROTEIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873570648     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.219     Document Type: Article

References (37)

1. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-1032.
2. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90: 1051-1060.
3. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M. CRM1 is responsible for intracellular transport meditted by the nuclear export signal. Nature 1997; 390: 308-311.
4. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 1997; 278: 141-144.
5. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997; 90: 1041-1050.
6. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr Opin Struct Biol 2010; 20: 782-790.
7. Kutay U, Guttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005; 15: 121-124.
8. Dong X, Biswas A, Chook YM. Structural basis of assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 2009; 16: 558-560.
9. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458: 1136-1141.
10. Guttler T, Madl T, Neumann P, Deichsel D, Corsini L, Monecke T et al. NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1. Nat Struct Mol Biol 2010; 17: 1367-1376.
11. Bonazzi S, Eidam O, Guttinger S, Wach JY, Zemp I, Kutay U et al. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc 2010; 132: 1432-1442.
12. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112-9117.
13. Meissner T, Krause E, Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004; 576: 27-30.
14. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009; 69: 510-517.
15. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 118: 3922-3931.
16. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008; 16: 9487-9497.
17. Wach JY, Guttinger S, Kutay U, Gademann K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett 2010; 20: 2843-2846.
18. Monecke T, Guttler T, Neumann P, Dickmanns A, Gorlich D, Ficner R. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 2009; 324: 1087-1091.
19. Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP et al. BCRABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006; 107: 1591-1598.
20. Kancha RK, von Bubnoff N, Miething C, Peschel C, Gotze KS, Duyster J. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica 2008; 93: 1718-1722.
21. Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009; 69: 6899-6905.
22. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-234.
23. Monovich L, Koch KA, Burgis R, Osimboni E, Mann T, Wall D et al. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta 2009; 1789: 422-431.
24. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-649.
25. Koyama M, Matsuura Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J 2010; 29: 2002-2013.
26. Chook YM, Blobel G. Structure of the nuclear transport complex karyopherinbeta2-Ran x GppNHp. Nature 1999; 399: 230-237.
27. Vagin A, Teplyakov A. MOLREP: an automated program for molecular replacement. J Appl Cryst 1997; 30: 1022-1025.
28. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60(Part 12, Part 1): 2126-2132.
29. CCP4. The CCP4 suite: programs for X-ray crystallography. Acta Crystallogr D 1994; 50: 760-763.
30. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53(Part 3): 240-255.
31. Painter J, Merritt EA. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 2006; 62(Part 4): 439-450.
32. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK-a program to check the stereochemical quality of protein structures. J App Cryst 1993; 26: 283-291.
33. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M et al. Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012; e-pub ahead of print 7 June 2012.
34. Bolli N, Payne EM, Grabher C, Lee JS, Johnston AB, Falini B et al. Expression of the cytoplasmic NPM1 mutant (NPMc\+) causes the expansion of hematopoietic cells in zebrafish. Blood 2010; 115: 3329-3340.
35. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al. Both carboxyterminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc\+ AML. Blood 2006; 107: 4514-4523.
36. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
37. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129-1133.